May be potentiated by systemic CYP3A4 inhibitors, dual CYP3A4/CYP1A2 inhibitors (eg, erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine); consider risks vs benefits prior to concomitant ...

Concomitant use or discontinuation of CYP2D6 inhibitors, CYP3A4 inhibitors ... Neonatal opioid withdrawal syndrome. Cytochrome P450 interactions. Hepatotoxicity. Risks from concomitant use with ...